Antibiotic-related adverse events in paediatrics: unique characteristics

References

• Tamma PD, Avdic E, Li DX, et al. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med. 2017;177:1308–1315.
   PubMed Web of Science ®Google Scholar
• Murphy JL, Fenn N, Pyle L, et al. Adverse events in pediatric patients receiving long-term oral and intravenous antibiotics. Hosp Pediatr. 2016;6:330–338.
   PubMedGoogle Scholar
• Esposito S, Principi N; European Society of Clinical Microbiology Infectious Diseases (ESCMID) Vaccine Study Group (EVASG). Influenza vaccination and prevention of antimicrobial resistance. Expert Rev Vaccines. 2018;17:881–888.
   PubMed Web of Science ®Google Scholar
• De Luca M, Donà D, Montagnani C, et al. Antibiotic prescriptions and prophylaxis in italian children. Is it time to change? data from the ARPEC project. PLoS One. 2016;11:e0154662.
   PubMed Web of Science ®Google Scholar
• Nash DR, Harman J, Wald ER, et al. Antibiotic prescribing by primary care physicians for children with upper respiratory tract infections. Arch Pediatr Adolesc Med. 2002;156:1114–1119.
   PubMed Web of Science ®Google Scholar
• McCaig LF, Besser RE, Hughes JM. Antimicrobial drug prescription in ambulatory care settings, United States, 1992–2000. Emerg Infect Dis. 2003;9:432–437.
   PubMed Web of Science ®Google Scholar
• Esposito S, Blasi F, Allegra L, et al. Use of antimicrobial agents for community-acquired lower respiratory tract infections in hospitalised children. Eur J Clin Microbiol Infect Dis. 2001;20:647–650.
   PubMed Web of Science ®Google Scholar
• Matalová P, Urbánek K, Anzenbacher P. Specific features of pharmacokinetics in children. Drug Metab Rev. 2016;48:70–79.
   PubMed Web of Science ®Google Scholar
• Downes KJ, Hahn A, Wiles J, et al. Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics. Int J Antimicrob Agents. 2014;43:223–230.
   PubMed Web of Science ®Google Scholar
• Thompson G, Barker CI, Folgori L, et al. Global shortage of neonatal and paediatric antibiotic trials: rapid review. BMJ Open. 2017;7:e016293.
   PubMed Web of Science ®Google Scholar
• Versporten A, Sharland M, Bielicki J, et al. The antibiotic resistance and prescribing in European Children project: a neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide. Pediatr Infect Dis J. 2013;32:e242–e53.
   PubMed Web of Science ®Google Scholar
• Sturkenboom MC, Verhamme KM, Nicolosi A, et al. Drug use in children: cohort study in three European countries. BMJ. 2008;337:a2245.0.
   PubMedGoogle Scholar
• Chua KP, Fischer MA, Linder JA. Appropriateness of outpatient antibiotic prescribing among privately insured US patients: ICD-10-CM based cross sectional study. BMJ. 2019;364:k5092.
   PubMedGoogle Scholar
• Principi N, Esposito S. Antimicrobial stewardship in paediatrics. BMC Infect Dis. 2016;16:424.
   PubMed Web of Science ®Google Scholar
• Mainous AG III, Hueston WJ, Davis MP, et al. Trends in antimicrobial prescribing for bronchitis and upper respiratory infections among adults and children. Am J Pub Health. 2003;93:1910–1914.
   PubMed Web of Science ®Google Scholar
• McCaig LF, Besser RE, Hughes JM. Trends in antimicrobial prescribing rates for children and adolescents. JAMA. 2002;287:3096–3102.
   PubMed Web of Science ®Google Scholar
• Miller GE, Hudson J. Children and antibiotics: analysis of reduced use, 1996–2001. Med Care. 2006;44(5 Suppl):I36–I44.
   PubMed Web of Science ®Google Scholar
• Rogawski ET, Platts-Mills JA, Seidman JC, et al. Use of antibiotics in children younger than two years in eight countries: a prospective cohort study. Bull World Health Organ. 2017;95:49–61.
   PubMed Web of Science ®Google Scholar
• Youngster I, Avorn J, Belleudi V, et al. Antibiotic use in children - a cross-national analysis of 6 countries. J Pediatr. 2017;182:239–44.e1.
   PubMed Web of Science ®Google Scholar
• Hersh AL, Jackson MA, Hicks LA. Principles of judicious antibiotic prescribing for upper respiratory tract infections in pediatrics. Pediatrics. 2013;132:1146–1154.
   PubMed Web of Science ®Google Scholar
• Porta A, Hsia Y, Doerholt K, et al. Comparing neonatal and paediatric antibiotic prescribing between hospitals: a new algorithm to help international benchmarking. J Antimicrob Chemother. 2012;67:1278–1286.
   PubMed Web of Science ®Google Scholar
• Levy ER, Swami S, Dubois SG, et al. Rates and appropriateness of antimicrobial prescribing at an academic children’s hospital, 2007–2010. Infect Control Hosp Epidemiol. 2012;33:346–353.
   PubMed Web of Science ®Google Scholar
• Cohen AL, Budnitz DS, Weidenbach KN, et al. National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents. J Pediatr. 2008;152:416–421.
   PubMed Web of Science ®Google Scholar
• Shehab N, Patel PR, Srinivasan A, et al. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis. 2008;47:735–743.
   PubMed Web of Science ®Google Scholar
• Lovegrove MC, Geller AI, Fleming-Dutra KE, et al. US emergency department visits for adverse drug events from antibiotics in children, 2011–2015. J Pediatric Infect Dis Soc. 2018; Epub Aug 23. DOI:10.1093/jpids/piy066.
   PubMedGoogle Scholar
• Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. Drug Saf. 2002;25:1–5.
   PubMed Web of Science ®Google Scholar
• McIntyre J, Conroy S, Avery A, et al. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child. 2000;83:498–501.
   PubMed Web of Science ®Google Scholar
• Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European network for drug investigation in children. BMJ. 2000;320:79–82.
   PubMed Web of Science ®Google Scholar
• Porta A, Esposito S, Menson E, et al. Off-label antibiotic use in children in three European countries. Eur J Clin Pharmacol. 2010;66:919–927.
   PubMed Web of Science ®Google Scholar
• Helal NF, Ghany EAGA, Abuelhamd WA, et al. Characteristics and outcome of newborn admitted with acute bilirubin encephalopathy to a tertiary neonatal intensive care unit. World J Pediatr. 2019;15:42–48.
   PubMed Web of Science ®Google Scholar
• Odell GB. Studies in kernicterus. I. The protein binding of bilirubin. J Clin Invest. 1959;38:823–833.
   PubMed Web of Science ®Google Scholar
• Andersen DH, Blanc WA, Crozier DN, et al. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics. 1956;18:614–625.
   PubMed Web of Science ®Google Scholar
• Thyagarajan B, Deshpande SS. Cotrimoxazole and neonatal kernicterus: a review. Drug Chem Toxicol. 2014;37:121–129.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Bactrim. Sulfamethoxazole and Trimethoprim; [cited 2019 Jun 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/017377s067lbl.pdf
   Google Scholar
• Strassburg CP, Strassburg A, Kneip S, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut. 2002;50:259–265.
   PubMed Web of Science ®Google Scholar
• Mulhall A, de Louvois J, Hurley R. The pharmacokinetics of chloramphenicol in the neonate and young infant. J Antimicrob Chemother. 1983;12:629–639.
   PubMed Web of Science ®Google Scholar
• Mulhall A, de Louvois J, Hurley R. Efficacy of chloramphenicol in the treatment of neonatal and infantile meningitis: a study of 70 cases. Lancet. 1983;1:284–287.
   PubMed Web of Science ®Google Scholar
• Mulhall A, Berry DJ, de Louvois J. Chloramphenicol in paediatrics: current prescribing practice and the need to monitor. Eur J Pediatr. 1988;147:574–578.
   PubMed Web of Science ®Google Scholar
• Modi N. Development of renal function. Br Med Bull. 1988;44:935–956.
   PubMed Web of Science ®Google Scholar
• Nielsen EI, Sandström M, Honoré PH, et al. Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. Clin Pharmacokinet. 2009;48:253–263.
   PubMed Web of Science ®Google Scholar
• Lopez-Novoa JM, Quiros Y, Vicente L, et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011;79:33–45.
   PubMed Web of Science ®Google Scholar
• Zappitelli M, Moffett BS, Hyder A, et al. Acute kidney injury in non-critically ill children treated with aminoglycoside antibiotics in a tertiary healthcare centre: a retrospective cohort study. Nephrol Dial Transplant. 2011;26:144–150.
   PubMed Web of Science ®Google Scholar
• Van Hecke R, Van Rompaey V, Wuyts FL, et al. Systemic aminoglycosides-induced vestibulotoxicity in humans. Ear Hear. 2017;38:653–662.
   PubMed Web of Science ®Google Scholar
• Jiang M, Karasawa T, Steyger PS. Aminoglycoside-induced cochleotoxicity: a review. Front Cell Neurosci. 2017;11:308.
   PubMed Web of Science ®Google Scholar
• Rao SC, Srinivasjois R, Hagan MA. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev. 2011;11:1–36.
   Google Scholar
• Reynolds L, Mailman T, McMillan D. Gentamicin in neonates at risk for sepsis - peak serum concentrations are not necessary. Paediatr Child Health. 2012;17:310–312.
   PubMed Web of Science ®Google Scholar
• Stach L, Pallotto E, Sandritter T. Development of criteria for gentamicin monitoring in a neonatal intensive care unit. Am J Health Syst Pharm. 2012;69:1319–1325.
   PubMed Web of Science ®Google Scholar
• Thureen PJ, Reiter PD, Gresores A, et al. Once- versus twice-daily gentamicin dosing in neonates >/=34 weeks’ gestation: cost-effectiveness analyses. Pediatrics. 1999;103:594–598.
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy S, Nair A, Furness J, et al. Gentamicin use in neonates: should we have a change of practice? Scott Med J. 2013;58:241–245.
   PubMed Web of Science ®Google Scholar
• Agarwal G, Rastogi A, Pyati S, et al. Comparison of once-daily versus twice-daily gentamicin dosing regimens in infants > or = 2500 g. J Perinatol. 2002;22:268–274.
   PubMedGoogle Scholar
• Koren K. Therapeutic drug monitoring principles in the neonate. Clin Chem. 1997;43:222–227.
   PubMed Web of Science ®Google Scholar
• Bamgbola O. Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab. 2016;7:136–147.
   PubMed Web of Science ®Google Scholar
• Vella-Brincat JW, Begg EJ, Robertshawe BJ, et al. Are gentamicin and/or vancomycin associated with ototoxicity in the neonate? A retrospective audit. Neonatol. 2011;100:186–193.
   PubMed Web of Science ®Google Scholar
• de Hoog M, Mouton JW. van den Anker JN. Vancomycin pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet. 2004;43:417–440.
   PubMed Web of Science ®Google Scholar
• Pacifici GM, Allegaert K. Clinical pharmacokinetics of vancomycin in the neonate: a review. Clinics (Sao Paulo). 2012;67:831–837.
   PubMed Web of Science ®Google Scholar
• Frymoyer A, Stockmann C, Hersh AL, et al. individualized empiric vancomycin dosing in neonates using a model-based approach. J Pediatric Infect Dis Soc. 2017; Epub Dec 27. DOI:10.1093/jpids/pix109.
   Web of Science ®Google Scholar
• Monteiro JF, Hahn SR, Gonçalves J, et al. Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations. Pharmacol Res Perspect. 2018;6:e00420.
   PubMed Web of Science ®Google Scholar
• Everett KV, Chioza BA, Georgoula C, et al. Genome-wide high-density SNP-based linkage analysis of infantile hypertrophic pyloric stenosis identifies loci on chromosomes 11q14-q22 and Xq23. Am J Hum Genet. 2008;82:756–762.
   PubMed Web of Science ®Google Scholar
• Lartey PA, Nellans HN, Tanaka SK. New developments in macrolides: structures and antibacterial and prokinetic activities. Adv Pharmacol. 1994;28:307–343.
   PubMedGoogle Scholar
• Jadcherla SR, Berseth CL. Effect of erythromycin on gastroduodenal contractile activity in developing neonates. J Pediatr Gastroenterol Nutr. 2002;34:16–22.
   PubMed Web of Science ®Google Scholar
• Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents. 2001;18(Suppl 1):S71–6.
   PubMedGoogle Scholar
• Principi N, Esposito S. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Saf. 1999;20:25–41.
   PubMed Web of Science ®Google Scholar
• Hassan SM, Mubarik A, Muddassir S, et al. Adult idiopathic hypertrophic pyloric stenosis - a common presentation with an uncommon diagnosis. J Community Hosp Intern Med Perspect. 2018;8:64–67.
   PubMed Web of Science ®Google Scholar
• Panteli C. New insights into the pathogenesis of infantile pyloric stenosis. Pediatr Surg Int. 2009;25:1043–1052.
   PubMed Web of Science ®Google Scholar
• Ezelarab HAA, Abbas SH, Hassan HA, et al. Recent updates of fluoroquinolones as antibacterial agents. Arch Pharm (Weinheim). 2018;351:e1800141.
   PubMed Web of Science ®Google Scholar
• Jackson MA, Schutze GE. The use of systemic and topical fluoroquinolones. Pediatrics. 2016;138:e20162706.
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Appropriate use of fluoroquinolones in children. Int J Antimicrob Agents. 2015;45:341–346.
   PubMed Web of Science ®Google Scholar
• Riecke K, Lozo E, Schwabe R, et al. Fluoroquinolone-induced lesions in the epiphyseal growth plates of immature rats. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17–20; Toronto, Canada.
   Google Scholar
• Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents. 2009;33:194–200.
   PubMed Web of Science ®Google Scholar
• Cross R, Ling C, NP D, et al. Revisiting doxycycline in pregnancy and early childhood–time to rebuild its reputation? Expert Opin Drug Saf. 2016;15:367–382.
   PubMed Web of Science ®Google Scholar
• Guggenheimer J. Tetracyclines and the human dentition. Compend Contin Educ Dent. 1984;5:245–248.
   PubMedGoogle Scholar
• Witkop CJ, Wolf RO. Hypoplasia and intrinsic staining of enamel following tetracycline therapy. JAMA. 1963;185:1008–1011.
   PubMed Web of Science ®Google Scholar
• Wormser GP, Wormser RP, Strle F, et al. How safe is doxycycline for young children or for pregnant or breastfeeding women? Diagn Microbiol Infect Dis. 2019;93:238–242.
   PubMed Web of Science ®Google Scholar
• Forti G, Benincori C. Doxycycline and the teeth. Lancet. 1969;1:782.
   PubMed Web of Science ®Google Scholar
• Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever–United States, 2013: recommendations from CDC and the Q Fever Working Group. MMWR Recomm Rep. 2013;62(RR–03):1–30.
   PubMedGoogle Scholar
• Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases: rocky mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis - United States. MMWR Recomm Rep. 2016;65:1–44.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines. Guidelines for the malaria treatment. 3rd ed; [cited 2019 Mar 12]. Available from: https://apps.who.int/iris/bitstream/handle/10665/162441/9789241549127_eng.pdf;jsessionid=82D4773A061B7B62B82C8DC0182AF793?sequence=1
   Google Scholar
• Tuohy KM, Fava F, Viola R. ‘The way to a man’s heart is through his gut microbiota’ e dietary pro- and prebiotics for the management of cardiovascular risk. Proc Nutr Soc. 2014;73:172e85.
   Web of Science ®Google Scholar
• Goel A, Gupta M, Aggarwal R. Gut microbiota and liver disease. J Gastroenterol Hepatol. 2014;29:1139e48.
   Google Scholar
• Wing MR, Patel SS, Ramezani A, et al. Gut microbiome in chronic kidney disease. Exp Physiol. 2016;101:471e7.
   Web of Science ®Google Scholar
• Endesfelder D, Zu Castell W, Ardissone A, et al. Compromised gut microbiota networks in children with anti-islet cell autoimmunity. Diabetes. 2014;63:2006e14.
   Web of Science ®Google Scholar
• Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut. 2014;63:1513e21.
   Web of Science ®Google Scholar
• Zackular JP, Baxter NT, Chen GY, et al. Manipulation of the gut microbiota reveals role in colon tumorigenesis. mSphere. 2015;1:e00001–15.
   PubMed Web of Science ®Google Scholar
• Simonyte Sjödin K, Vidman L, Rydén P, et al. Emerging evidence of the role of gut microbiota in the development of allergic diseases. Curr Opin Allergy Clin Immunol. 2016;16:390–395.
   PubMed Web of Science ®Google Scholar
• Brusaferro A, Cozzali R, Orabona C, et al. Is it time to use probiotics to prevent or treat obesity? Nutrients. 2018;10:E1613.
   PubMed Web of Science ®Google Scholar
• Saari A, Virta LJ, Sankilampi U, et al. Antibiotic exposure in infancy and risk of being overweight in the first 24 months of life. Pediatrics. 2015;135:617–626.
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Antibiotic administration and the development of obesity in children. Int J Antimicrob Agents. 2016;47:171–177.
   PubMed Web of Science ®Google Scholar
• Neuman H, Forsythe P, Uzan A, et al. Antibiotics in early life: dysbiosis and the damage done. FEMS Microbiol Rev. 2018;42:489–499.
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Gut microbiota and central nervous system development. J Infect. 2016;73:536–546.
   PubMed Web of Science ®Google Scholar
• Umbrello G, Esposito S. Microbiota and neurologic diseases: potential effects of probiotics. J Transl Med. 2016;14:298.
   PubMed Web of Science ®Google Scholar
• Nathwani D, Varghese D, Stephens J, et al. Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review. Antimicrob Resist Infect Control. 2019;8:35.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine (US). Addressing the barriers to pediatric drug development. workshop summary. Washington (DC): National Academies Press (US); 2008.
   Google Scholar
• European Medicine Agency. European Medicines Agency and European Commission (DG Health and Food Safety) action plan on paediatrics; [cited 2019 Mar 12]. Available from: https://www.ema.europa.eu/en/documents/report/european-medicines-agency-european-commission-dg-health-food-safety-action-plan-paediatrics_en.pdf
   Google Scholar